Back to discover
Drug

Lebrikizumab

Approved · EMA
ClassInterleukin-13 inhibitorEmerging researchLate-stage development

Also known as Ebglyss.

RxNorm2693758ChEMBLCHEMBL1743035ATCD11AH10UNIIU9JLP7V031
1
Research papers
12
Active clinical trials
Interleukin-13
Primary target
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Utilization of a Cutaneous Therapy In Situ Microdevice

Clinical trial2026-06-03Results expected Q2 2030 · ClinicalTrials.gov

Evaluating the Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients: A 24-Week Study

Clinical trial2026-06-02Results expected Q4 2027 · ClinicalTrials.gov

A Phase 1, Randomized, Two-part, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity and Pharmacodynamics of LAD106 in Healthy Adult Participants

Clinical trial2026-05-15Results expected Q2 2027 · ClinicalTrials.gov

A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study With a Double-Blind Extension Evaluating Efficacy and Safety of Lebrikizumab Administered to Adult Patients With Nummular Eczema Who Are Not Adequately Controlled With Topical Corticosteroids or When This Treatment is Not Medically Advisable (LUMINE)

Clinical trial2026-05-14Results expected Q3 2028 · ClinicalTrials.gov

A Phase 4, Multicenter, Open-label, Single-arm Study to Investigate the Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate Atopic Dermatitis and High Itch Burden

Clinical trial2026-05-14Primary completion · ClinicalTrials.gov

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

Clinical trial2026-05-13Primary completion · ClinicalTrials.gov

A Phase 3, Multicenter, Long-Term Extension Study to Assess the Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Clinical trial2026-05-06Results expected Q4 2027 · ClinicalTrials.gov

A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Dermatitis

Clinical trial2026-04-23Completed · ClinicalTrials.gov

A Phase 3, 2-Part, Open-Label and Double-Blind, Randomised Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

Clinical trial2026-04-21Results expected Q2 2027 · ClinicalTrials.gov

An Open-Label, 24-Week Study to Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Clinical trial2026-03-09Results posted · ClinicalTrials.gov

Approval: Ebglyss (EMA)

Regulatory2023-11-16EMA

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.

Research2020-04-01JAMA dermatology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Lebrikizumab
Aliases & brands
Ebglyss
RxNorm CUI
2693758
ChEMBL ID
CHEMBL1743035
ATC codes
D11AH10
UNII
U9JLP7V031
Primary mechanism
Interleukin-13 inhibitor
Regulatory jurisdictions
ema

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Interleukin-13
IL13 · P35225
INHIBITORInterleukin-13 inhibitor

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2023-11-16
Latest approval
2023-11-16
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2023-11-16Approval
Approval: Ebglyss (EMA)
Indication: Ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates… Show full indication

Ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

44 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
44
registered trials across all phases
LATEST COMPLETION 2026
12
Active studies
6
Recruiting
26
Late-stage (III+)
30
Completed
2
Discontinued
PHASE DISTRIBUTIONn = 44
Phase 15Phase 213Phase 323Phase 43

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Utilization of a Cutaneous Therapy In Situ Microdevice

Not yet recruitingPH IVUniversity of California, San Franciscon=102030

A Phase IV, Non-randomized, Open-label Multinational Trial to Assess the Mechanism of Action for Lebrikizumab in Moderate-to-severe Atopic Dermatitis

RecruitingPH IVJohann E Gudjonsson MD PhDn=482027

A Phase 4, Multicenter, Open-label, Single-arm Study to Investigate the Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate Atopic Dermatitis and High Itch Burden

Active, not recruitingPH IVEli Lilly and Companyn=2332026

A Phase 3, Multicenter, Long-Term Extension Study to Assess the Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Enrolling by invitationPH IIIEli Lilly and Companyn=3102029

A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study With a Double-Blind Extension Evaluating Efficacy and Safety of Lebrikizumab Administered to Adult Patients With Nummular Eczema Who Are Not Adequately Controlled With Topical Corticosteroids or When This Treatment is Not Medically Advisable (LUMINE)

Not yet recruitingPH IIIAlmirall, S.A.n=2702029

Recent completions

Trials that read out recently, adding to the completed evidence base.

A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Dermatitis

CompletedPH IIIAlmirall, S.A.n=1742026

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)

CompletedPH IIIKey trialEli Lilly and Companyn=1,1532025

An Open-Label, 24-Week Study to Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

CompletedPH IIIEli Lilly and Companyn=902025

An Open-Label Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

CompletedPH IIIEli Lilly and Companyn=862025

A Phase 1, Participant- and Investigator-blinded, Randomized, Single-dose Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants

CompletedPH IEli Lilly and Companyn=242024

A Randomised, Double-Blind, Placebo-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adult and Adolescent Patients With Moderate-To-Severe Atopic Dermatitis That Are Not Adequately Controlled With Cyclosporine or For Whom Cyclosporine is Not Medically Advisable.

CompletedPH IIIAlmirall, S.A.n=3312024

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Journals, researchers & institutions
Top journals
  • JAMA dermatology1
Leading researchers
  • Armstrong AW1
  • Blauvelt A1
  • Drew J1
  • Eichenfield LF1
  • Gopalan R1
  • Guttman-Yassky E1
  • Paller AS1
  • Simpson EL1
Leading institutions
free-text, unnormalised
  • Feinberg School of Medicine1
  • Icahn School of Medicine at Mount Sinai1
  • Keck School of Medicine1
  • Oregon Health & Science University1
  • Oregon Medical Research Center1
  • Rady Children's Hospital1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.